Anlon Healthcare IPO 2025: Complete Guide and Detailed Analysis

IPO Allotment Status: Click Here  

Anlon Healthcare Limited’s IPO in 2025 is attracting significant interest from investors looking to capitalize on the growing pharmaceutical sector in India. This detailed blog post provides a comprehensive overview of the company, its financials, IPO details, investment prospects, risks, and much more, specifically structured to aid investors and readers in making well-informed decisions. The content is developed to cover a minimum of 1500 words to suit an in-depth blog post.

---

Introduction to Anlon Healthcare Limited

Anlon Healthcare Limited, headquartered in Rajkot, Gujarat, is a pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and nutraceuticals. Since commencing manufacturing operations in 2017, the company has focused on producing high-purity APIs and intermediates used in pharmaceuticals, personal care, and animal health products.

The company operates a single, well-certified manufacturing facility conforming to ISO 9001:2015, Good Manufacturing Practice (GMP), and WHO-GMP standards, adhering to global quality benchmarks for pharmaceutical production. Anlon Healthcare's client base comprises reputed pharmaceutical companies both within India and some international markets, contributing to its growing footprint in this niche but vital sector.

---

IPO Overview and Key Details

Issue Size and Type

Anlon Healthcare’s IPO is a book-building issue aggregating up to ₹121.03 crore, comprising a fully fresh issue of approximately 1.33 crore equity shares. This fresh issue will raise capital primarily to fund operations and expansion.

Date and Price Band

• Opening Date: August 26, 2025
• Closing Date: August 29, 2025
• Price Band: ₹86 to ₹91 per share
• Face Value: ₹10 per share
• Lot Size: 164 shares (minimum application amount of about ₹14,924)
• Listing Date: Tentatively September 3, 2025
• Exchanges: BSE and NSE

Issue Type

This is an entirely fresh issue, meaning no offer for sale by existing shareholders. The capital raised will be used for corporate expansion and operational needs.

Registrar and Allotment

Kfin Technologies Limited is the registrar managing the IPO allotment process, refund, and share credit to investors.

---

Purpose and Use of Proceeds

Purpose	Estimated Allocation (₹ crores)	Percentage Allocation
Capital Expenditure for Expansion	30.71	25.37%
Working Capital Requirements	43.15	35.65%
Prepayment/Repayment of Borrowings	5.00	4.00%
General Corporate Purposes and Miscellaneous	42.17	35.00%

The capital raised is primarily targeted at expanding manufacturing capacity, enhancing working capital for order fulfillment, prepaying certain borrowings to reduce interest burdens, and general corporate purposes to maintain operational flexibility.

---

Company Financial Performance

Revenue and Profit Growth

Financial Metric	FY 2025 (₹ crore)	FY 2024 (₹ crore)	Growth (%)
Revenue	120.46	66.69	+81%
Profit After Tax (PAT)	20.52	9.66	+112%
EBITDA Margin (%)	26.88	Not Available	-
Earnings Per Share (EPS)	₹5.15	Not Available	-

Anlon Healthcare has witnessed remarkable revenue growth, nearly doubling from ₹66.7 crore in FY 2024 to over ₹120 crore in FY 2025. The profit after tax similarly surged by 112%, reflecting enhanced operational efficiencies and scale economics.

Key Ratios

• Price-Earnings (PE) Ratio: 17.67x (Indicates relatively reasonable valuation)
• Return on Net Worth (RoNW): 25.51%
• Return on Capital Employed (ROCE): 21.93%
• Return on Equity (ROE): 40.45%
• Price to Book Value: 4.51x

These metrics suggest the company operates profitably with strong returns to shareholders and sound operational controls.

---

Business Strengths

• Certified Manufacturing Facility: WHO GMP, ISO 9001:2015, GMP approved facility assuring compliance with strict global pharmaceutical standards.
• Diverse Product Portfolio: Offering APIs, pharmaceutical intermediates, and nutraceuticals with applications across multiple sectors such as human medicine and animal health.
• Strong Client Relationships: Associations with leading pharmaceutical companies within India and exports to select international markets.
• High Barrier to Entry: Stringent regulatory approvals and quality certifications limit competition.
• Focus on Quality, Environment, Health & Safety (QEHS): Continuous focus on quality and EH&S compliance enhances sustainability and regulatory approval prospects.

---

IPO Subscription and Market Sentiment

Grey Market Premium (GMP)

• As of August 26, 2025, the GMP stood at ₹5 per share over the IPO price band peak ₹91, suggesting a potential estimated listing price around ₹96 and expected listing gain of approximately 5.49%.
• The IPO has garnered substantial interest, particularly from retail investors, demonstrating confidence in the company’s fundamentals and growth potential.

Subscription Statistics (as of 26th August 2025 at 5 PM)

Category	Reserved Shares (Lakhs)	Applied Shares (Lakhs)	Subscription Ratio (X times)
Institutional	99.75	90.89	0.91x
Non-Institutional Investors (NII)	19.95	14.13	0.71x
Retail	13.30	119.39	8.98x
Total	133.00	224.41	1.69x

The retail segment shows strong subscription multiples, indicating keen interest from individual investors.

---

Risks and Considerations for Investors

Despite the promising outlook, potential investors should carefully weigh the following risks:

• Revenue Concentration Risk: Dependence on a handful of large customers contributes a significant portion of revenues (~78% for top 10 customers), limiting diversification.
• Single Manufacturing Facility: Operating from one location exposes them to operational disruptions, natural disasters, or regulatory issues at that site.
• Regulatory Approvals: Stringent pharma regulations cause delays and costs in approvals, impacting timelines and revenues.
• Competitive Industry: Intense competition from domestic and multinational API manufacturers could compress margins and market share.
• Financial Leverage: Increasing borrowings for expansion could create interest burden and solvency concerns if business scales slower than anticipated.
• Volatile Raw Material Prices: Fluctuations in raw material costs can affect profitability, as contracts with clients may not always enable immediate price adjustments.

---

Investment Outlook

Anlon Healthcare is positioned in a high-potential niche within the Indian pharmaceutical landscape. With increasing demand for quality APIs and intermediates fueled by India's growing pharmaceutical production, the company stands to benefit substantially from capacity expansion funded by the IPO.

The improvements in revenue and profit performance, alongside a disciplined approach to quality and compliance, help underpin a positive investment thesis. The IPO offers retail and institutional investors an opportunity to get early equity participation in a focused, niche pharma company with strong growth and margin expansion potential.

---

Important IPO Dates and Summary Table

Attribute	Information
IPO Open Date	August 26, 2025
IPO Close Date	August 29, 2025
Price Band	₹86 to ₹91 per share
Lot Size	164 shares (~₹14,924)
Issue Size	₹121.03 crore (entirely fresh issue)
Face Value	₹10 per share
Listing Date	September 3, 2025 (tentative)
Exchanges	BSE and NSE
Registrar	Kfin Technologies Pvt. Ltd.

---

How to Apply for Anlon Healthcare IPO

Applicants can subscribe online through their Demat accounts by following these steps:

1. Log into your broker’s platform or stock trading app.
2. Locate the Anlon Healthcare IPO section.
3. Enter the bid quantity (multiple of 164 shares).
4. Select a bid price within the ₹86-91 band.
5. Submit your application.
6. Use UPI payment or ASBA facility to block the required amount until allotment.
7. After allotment, shares will be credited to your Demat account, and any excess funds refunded.

The allotment status can be tracked on the registrar’s website or stock exchange portal after the issue closes.

---

Conclusion

Anlon Healthcare IPO 2025 represents an attractive entry point into a growing pharmaceutical niche with strong fundamentals, good governance, and a transparent capital-raising structure. Backed by impressive growth in revenues and profits, stringent quality certifications, and a clear plan for expansion, the company is well-positioned for sustainable growth.

While inherent risks, such as client concentration and regulatory complexities, should be considered, investors seeking pharma sector exposure might find this IPO appealing. Keen retail investor interest and reasonable valuations additionally support its potential.

Potential investors should evaluate their risk tolerance, study detailed financial disclosures, and seek professional advice where necessary before investing.

---

Disclaimer

This blog is for informational purposes only and does not constitute investment advice. Investing in IPOs involves risks including capital loss and market volatility. Readers should perform their own due diligence or consult financial advisors before investing.